Recursion Pharmaceuticals Stock Fair Value – RECURSION PHARMACEUTICALS Reports Total Revenue of USD 10.1 Million in Q3 of 2023, Down 22.6% Year-on-Year
November 21, 2023
🌥️Earnings Overview
On November 9, 2023, RECURSION PHARMACEUTICALS ($NASDAQ:RXRX) reported total revenue of USD 10.1 million for the third quarter of fiscal year 2023, a 22.6% decrease compared to the same period of the previous year.
Analysis – Recursion Pharmaceuticals Stock Fair Value
GoodWhale has taken a deep dive into the fundamentals of RECURSION PHARMACEUTICALS and their analysis has revealed that the intrinsic value of the company’s stock is around $36.5. This figure was determined using GoodWhale’s proprietary Valuation Line, which takes into account the risk profile of the company, the financials, and the industry they operate in. Currently, the stock is being traded at just $5.2, making it an undervalued stock by 85.8%. This means that investors have an incredible opportunity to purchase shares at a significant discount and benefit from future growth when RECURSION PHARMACEUTICALS share price returns to its intrinsic value. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Recursion Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 46.93 | -292.56 | -623.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Recursion Pharmaceuticals. More…
| Operations | Investing | Financing |
| -258.45 | -15.72 | 206.73 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Recursion Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 630.83 | 192.86 | 2.03 |
Key Ratios Snapshot
Some of the financial key ratios for Recursion Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 185.2% | – | -623.2% |
| FCF Margin | ROE | ROA |
| -589.3% | -40.3% | -29.0% |
Peers
The company was founded in 2013 by Christopher R. Gibson and Brendan Frey. Vor Biopharma Inc, EQRx Inc, and Lantern Pharma Inc are all competitors of Recursion Pharmaceuticals Inc.
– Vor Biopharma Inc ($NASDAQ:VOR)
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with serious and life-threatening diseases. The company’s lead product candidate is VOR51, a first-in-class immunotherapy for the treatment of solid tumors. Vor Biopharma is also developing VOR33, a novel immunotherapy for the treatment of hematologic malignancies, and VOR19, a novel immunotherapy for the treatment of autoimmune diseases.
– EQRx Inc ($NASDAQ:EQRX)
EQRx is a biopharmaceutical company that focuses on the development of innovative therapies for patients with serious diseases. The company has a market cap of $2.42 billion and a return on equity of -12.39%. EQRx is headquartered in Cambridge, Massachusetts.
– Lantern Pharma Inc ($NASDAQ:LTRN)
Lantern Pharma Inc has a market cap of 46.57M as of 2022. The company’s return on equity is 16.74%.
Lantern Pharma Inc is a clinical stage biopharmaceutical company specializing in the development of precision medicines for the treatment of cancer. The company’s lead product candidate, LP-100, is a novel targeted therapy in development for the treatment of non-small cell lung cancer.
Summary
Recursion Pharmaceuticals reported total revenue of USD 10.1 million for the third quarter of fiscal year 2023, a 22.6% decrease from the same period in the previous year. Net income was USD -93.0 million, a further decrease from -60.4 million reported last year. The stock price decreased in response to the news, prompting investors to re-evaluate their investment in the company. While the revenue and net income figures suggest a poor financial performance, investors should consider all available information when evaluating Recursion Pharmaceuticals for potential investment opportunities.
Related Posts
Recent Posts
